Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Efficacy remains unproven in healthy populations
Gastrointestinal symptoms and occasional psychiatric concerns require monitoring
Structured targets improve consistency and long-term adherence to eating plans
AOD-9604 and MOTS-c are currently not approved by the FDA as drugs for treating specific medical conditions, though they are commonly used for improving metabolic efficiency
Patients on this protocol who also use metabolic support agents like Metformin should note that both agents activate AMPK, and physician oversight is warranted to avoid compounding effects on blood glucose that could theoretically cause hypoglycemia in susceptible individuals, though this has not been reported clinically with MOTS-c at standard doses
PeptideDeck does not condone the use of research peptides outside of legitimate research settings
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
